The monitoring of chimerism has become a routine diagnostic instrument at centers performing allogeneic stem cell or bone marrow transplantation. Despite the widespread use of molecular techniques permitting the assessment and the surveillance of donor-and recipient-derived hemopoiesis, there have, so far, been no international efforts to standardize the technical approaches and thus provide a basis for the comparison of diagnostic results. We are trying to fill this gap. Indeed, in this field there is an obvious and urgent need for the standardization of techniques and interpretation of them, otherwise we shall not be able to see the forest for the trees. Our scientific resources will in part be depleted and, in medical centers, not enough patients will benefit from optimal diagnosis and, subsequently, from optimal treatment.
The Debate Round- . In this issue, LEUKEMIA presents new contributions to the Debate, illustrating some of the ideas that we hope will stimulate further discussion about the important aspects of chimerism analysis. The first paper (Fernández-Avilés et al) addresses the role of chimerism testing within the T-cell and myeloid-cell compartments for assessing the risk of graft rejection and relapse in myeloid leukemias. The second paper (Maas et al) presents the use of real-time PCR for the investigation of chimerism, based on the analysis of single nucleotide polymorphisms. The technique described is an important addition to the spectrum of methods applicable to the investigation of chimerism, permitting highthroughput analysis at a sensitivity superior to most other approaches.
Based on the results of this debate and the current state of the art, we would like to establish consensus for chimerism testing, hopefully opening up on therapeutic implications. In the clinically oriented part of the debate, we would like to discuss the optimum timing of chimerism analysis after transplantation and the therapy options inferable herein for different transplant settings.
Contributions to the Debate should be labeled 'Round Table  on Chimerism Testing', and sent to the LEUKEMIA office in Paris, which will transmit the manuscripts to the guest Editor of the Debate (T. Lion). There is no limitation to the number of participants in the Debate. The contributions can be short notes of up to 2500 words with a few references, regular papers or editorials.
